Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.96
(30.67%)
USD 1.96
(30.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 221.67 Million USD | 71.35% |
| 2021 | 129.36 Million USD | -9.11% |
| 2020 | 142.33 Million USD | 5.44% |
| 2019 | 134.99 Million USD | -10.83% |
| 2018 | 151.39 Million USD | -15.67% |
| 2017 | 179.52 Million USD | 33.8% |
| 2016 | 134.17 Million USD | 165.27% |
| 2015 | 50.58 Million USD | 584.9% |
| 2014 | 7.38 Million USD | 17.26% |
| 2013 | 6.29 Million USD | 1104.48% |
| 2012 | -627 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | 47.78 Million USD | -2.48% |
| 2023 Q1 | 49 Million USD | 20.01% |
| 2022 Q1 | 88.11 Million USD | 193.62% |
| 2022 FY | 221.67 Million USD | 71.35% |
| 2022 Q2 | 50.47 Million USD | -42.72% |
| 2022 Q3 | 42.25 Million USD | -16.29% |
| 2022 Q4 | 40.83 Million USD | -3.35% |
| 2021 FY | 129.36 Million USD | -9.11% |
| 2021 Q3 | 31.59 Million USD | -15.45% |
| 2021 Q4 | 30.01 Million USD | -5.01% |
| 2021 Q2 | 37.36 Million USD | 22.94% |
| 2021 Q1 | 30.39 Million USD | -18.68% |
| 2020 Q3 | 37.94 Million USD | 31.73% |
| 2020 Q1 | 38.21 Million USD | 4.23% |
| 2020 Q2 | 28.8 Million USD | -24.63% |
| 2020 Q4 | 37.37 Million USD | -1.49% |
| 2020 FY | 142.33 Million USD | 5.44% |
| 2019 Q2 | 35.41 Million USD | -3.45% |
| 2019 Q4 | 36.66 Million USD | 39.82% |
| 2019 Q3 | 26.22 Million USD | -25.96% |
| 2019 FY | 134.99 Million USD | -10.83% |
| 2019 Q1 | 36.68 Million USD | -2.17% |
| 2018 Q3 | 38.34 Million USD | -5.87% |
| 2018 Q2 | 40.73 Million USD | 17.0% |
| 2018 Q1 | 34.81 Million USD | 5.26% |
| 2018 FY | 151.39 Million USD | -15.67% |
| 2018 Q4 | 37.49 Million USD | -2.21% |
| 2017 Q4 | 33.07 Million USD | -35.59% |
| 2017 Q2 | 36.28 Million USD | -38.28% |
| 2017 Q1 | 58.79 Million USD | -5.65% |
| 2017 FY | 179.52 Million USD | 33.8% |
| 2017 Q3 | 51.35 Million USD | 41.52% |
| 2016 Q1 | 15 Million USD | -3.73% |
| 2016 Q4 | 62.32 Million USD | 127.39% |
| 2016 Q3 | 27.4 Million USD | -6.92% |
| 2016 Q2 | 29.44 Million USD | 96.27% |
| 2016 FY | 134.17 Million USD | 165.27% |
| 2015 Q4 | 15.58 Million USD | 685.83% |
| 2015 FY | 50.58 Million USD | 584.9% |
| 2015 Q3 | 1.98 Million USD | -25.28% |
| 2015 Q2 | 2.65 Million USD | -91.26% |
| 2015 Q1 | 30.36 Million USD | 2632.76% |
| 2014 Q3 | 637 Thousand USD | -84.96% |
| 2014 FY | 7.38 Million USD | 17.26% |
| 2014 Q4 | 1.11 Million USD | 74.41% |
| 2014 Q2 | 4.23 Million USD | 157.48% |
| 2014 Q1 | 1.64 Million USD | 89.68% |
| 2013 Q2 | 2.14 Million USD | 84.12% |
| 2013 Q1 | 1.16 Million USD | -8.19% |
| 2013 Q3 | 1.7 Million USD | -20.53% |
| 2013 FY | 6.29 Million USD | 1104.48% |
| 2013 Q4 | 867.37 Thousand USD | -49.23% |
| 2012 Q3 | 464.42 Thousand USD | 0.0% |
| 2012 Q4 | 1.27 Million USD | 173.87% |
| 2012 FY | -627 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bright Green Corporation | -237.01 Thousand USD | 93627.019% |
| BioQuest Corp. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -3281.239% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -4009.246% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | -56.39 Thousand USD | 393187.795% |
| Instadose Pharma Corp. | - USD | -Infinity% |